ロード中...
Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution
BACKGROUND: Only 15–20% of pancreatic ductal adenocarcinoma (PDAC) patients are upfront surgical candidates at presentation, and for this cohort of patients, the 5-year survival is a mere 20% despite adjuvant therapy. Previous data indicate that in clinical practice most of these cases are “borderli...
保存先:
| 出版年: | Ann Pancreat Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7170377/ https://ncbi.nlm.nih.gov/pubmed/32313882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2020.02.01 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|